Aberrant Wnt signaling mediated by mutations affecting APC (adenomatous polyposis coli) or b-catenin initiates the majority of human colorectal cancers (CRC) and drives tumorigenesis through the activation of specific genes such as MYC. We report here a novel association whereby another oncogenic transcription factor, MYB/c-Myb, is necessary for intestinal adenoma development directed by activated Wnt signaling. APC Min/ þ mice in which c-myb is haploinsufficient survive longer than wildtype APC Min/ þ animals due to a delay in adenoma formation. Intestinal adenomas from APC Min/ þ mice were assessed and found to have high levels of c-myc gene expression. We explored the relationship between activated Wnt signaling and MYB in regulating MYC and found activated b-catenin in combination with MYB induces robust upregulation of MYC promoter activity, as well as endogenous MYC mRNA and protein expression, in human cells. This cooperation occurred through independent binding of MYB and b-catenin to the MYC promoter. These data highlight a cooperative function for MYB in the context of activated Wnt signaling and provide a molecular basis for the expression of MYC in CRC. Robust expression of the transcription factor MYB/c-Myb is principally restricted to immature cells in the hemopoietic system and colon epithelium. Experiments in c-myb mutant mice show that two copies of the c-myb gene are required for cell survival during emergency responses to cytotoxic damage in both these compartments.
Robust expression of the transcription factor MYB/c-Myb is principally restricted to immature cells in the hemopoietic system and colon epithelium. Experiments in c-myb mutant mice show that two copies of the c-myb gene are required for cell survival during emergency responses to cytotoxic damage in both these compartments. 1 In addition, colonspecific loss of Myb disrupts not only colon formation in the developing mouse, but also crypt homeostasis in adults. 2 Levels of MYB expression become progressively higher as human colonic epithelium undergoes transformation whereas persistent expression blocks cytodifferentiation in both mouse and human colon cells. A large number of colorectal cancer (CRC) cell lines and clinical samples show elevated levels of MYB, with altered transcriptional elongation control underpinning this increase. 1 Nevertheless, in the context of CRC development, the primary focus in both mouse and human cells has been on canonical Wnt signaling through b-catenin activation.
b-Catenin is normally targeted for degradation by a complex of proteins including APC, AXIN, and glycogen synthase kinase-3b. 3, 4 Wnt binding to its receptor disrupts this complex and leads to the cytoplasmic stabilization of de novo synthesized and non-phosphorylated b-catenin.
5 b-Catenin subsequently translocates to the nucleus where it associates with TCF/LEF factors. This partnership converts b-catenin into a transcriptional activator and enhances the expression of Wnt target genes, such as MYC and CYCLIND1, which in turn promote colon transformation. A number of reports indicate that mutations in APC or CTNNB1 (b-catenin) initiate the majority of CRC. [6] [7] [8] [9] Given that a significant proportion of CRC isolates overexpress MYB and that this likely occurs in a background of activated Wnt signaling, we considered the contribution that MYB makes to CRC development initiated by Wnt pathway activation. We report here the convergence of MYB expression with Wnt signaling in regulating intestinal adenoma formation. In vivo mouse studies showed that reduced c-myb expression positively affects survival and that c-myb expression is a necessary feature of the carcinogenic process initiated by activated Wnt signaling. Further, to understand how c-Myb is contributing to CRC formation, expression profiling studies were undertaken, confirming a significant correlation between c-myb and c-myc expression in adenomas from APC Min/ þ mice and in human CRC. As the human MYC and mouse c-myc promoter landscapes are rich with previously characterized TCF/LEF and MYB binding sites, we explored the possibility that MYB cooperates with b-catenin to activate MYC transcription directly. Molecular analysis confirmed that MYB and b-catenin are required in concert to enhance activation of reporters containing the human MYC promoter. This effect was mirrored when endogenous MYC gene expression was followed and occurred through the binding of both factors to the MYC promoter. These binding events induced distinct changes in histone acetylation. These findings thus further the paradigm of intestinal adenoma development through Wnt pathway activation by demonstrating the need for MYB as an accessory factor to drive MYC overexpression and subsequent colonic neoplasia.
Results

Maximum adenoma formation in APC
Min/ þ mice is c-myb dependent. To explore the potential relationship between MYB and Wnt signaling in CRC development, we took a genetic approach whereby APC Min/ þ mice were crossed with Myb þ /À mice, extending the observation that APC Min/ þ mice have a prolonged life span when crossed onto a c-myc
background. 10 Although APC Min/ þ mice started to show signs of distress by week 10, including wasting and bleeding from the anus, APC Min/ þ mice on a c-myb þ /À background showed delayed onset of symptoms. When equal numbers of APC Min/ þ male and female mice were followed over time, APC Min/ þ mice on a c-myb þ /À background survived significantly longer before developing symptoms severe enough to require mandatory killing (P ¼ 0.01; unpaired t-test) (Figure 1a ). On average these mice survived beyond the death of all mice in the APC Min/ þ cohort (P ¼ 0.03; logrank (Mantel-Cox) test) (Figure 1b) . These results clearly demonstrate that c-Myb is a critical determinant of adenoma progression initiated through the deregulation of Wnt signaling.
Coordinate expression of c-myb and c-myc in adenomas from APC Min/ þ mice. It is evident that factors such as activated b-catenin and MYB promote tumorigenesis by regulating the activity of specific genes, particularly those having well-established functions in the carcinogenic process such as CYCLIND1, MYC, and COX-2.
4,11-13 Specifically, many studies point to the involvement of b-catenin in the activation of MYC in CRC, whereas activation of the human MYC promoter and endogenous gene by MYB/c-Myb has also been established. 14, 15 To continue exploring the relationship between activated Wnt signaling and MYB, we used real-time PCR to assess expression of c-myc in intestinal adenomas developing in APC Min/ þ mice ( Figure 1c ). As expected from previous analyses, c-myc mRNA expression was markedly increased in adenomas from both the colon and small intestine (SI). 10, 16 Furthermore, consistent with earlier reports and data from our own lab, c-myb mRNA expression was similarly elevated in adenomas from both sites ( Figure 1d ).
As c-myb haploinsufficiency significantly impeded the rate of adenoma formation in APC Min/ þ mice and c-myc expression concordantly increased in these adenomas, the relative levels c-myc mRNA in adenomas formed in APC Min/ þ Â c-myb þ /À mice were accordingly investigated. In a series of adenomas taken from both the SI and colon of double heterozygous mice, c-myc levels were significantly lower than in an equivalent series removed from APC Min/ þ mice (Po0.0001 and o0.006, respectively). Furthermore, c-myb MYC expression correlates with MYB expression in human CRC. To link these expression data from adenomaprone APC Min/ þ mice to human CRC, mRNA expression analysis of 229 tumor samples belonging to 13 histological types, including colon, was performed focusing on MYB and MYC and standardized against an 11-cell-line set frequently used for this type of comparison. 17 These data, represented by a fold expression plot, emphasized consistently high MYB expression in CRC, as well as breast and gastric cancers (Figure 2a) . When data for MYB and MYC were analyzed for each CRC alone and plotted for relative expression, an apparent association between MYB and MYC expression was evident (Figure 2b ). The relative expression of b-catenin mRNA was also plotted to highlight the lack of correlation between the expression level of this gene and MYC (Figure 2b ). This is consistent with literature showing that the mode of activation for b-catenin is typically at the level of protein abundance and/or localization rather than increases in mRNA expression levels. 3, 4 A correlation coefficient of r ¼ 0.51 between MYB and MYC expression in CRC was calculated using the cDNA microarray data from 23 CRC specimens (Figure 2c coexpression of MYB and MYC in all other cancers was 17-fold lower (r ¼ 0.03, P ¼ 0.651), indicating that the observed correlation between MYB and MYC is highly significant in human CRC compared to 12 other cancer types.
siRNA knockdown of MYB reduces MYC expression in CRC cells. In view of the observations that MYB and MYC were coordinately upregulated in adenomas developing in APC Min/ þ mice and coexpressed in human CRC where mutations in APC prevail, we pursued the relationship between MYB and MYC in a context of activated Wnt signaling. Although MYB and MYC are commonly overexpressed in CRC cells, the potential dependency of MYC expression on MYB has not been explored in this cancer type. We therefore used lentivirus infection to generate stable pools of Colo201 CRC cells that expressed either a doxycycline-inducible shRNA against MYB or a scrambled sequence control. Colo201 CRC cells express robust levels of MYB and MYC and also harbor activating mutations in the Wnt pathway. 18, 19 When MYB expression in this cell line is inhibited by induction of the shRNA (Figure 3a ), we observed a corresponding decline in MYC expression ( Figure 3b) . Notably, the scrambled sequence control also led to some reduction in MYB expression when in the presence of doxycycline. The basis for this was unclear, but again emphasized that MYC expression levels in a background of activated Wnt signaling are influenced by the presence of MYB. Taken together, our results suggest involvement of MYB in the maintenance of MYC expression in CRC cells where canonical Wnt pathway mutations are also present.
b-Catenin does not induce MYB expression. The common upregulation of MYB and MYC in both CRC cells and murine adenomas harboring Wnt pathway activation suggested the possibility that in addition to MYC, activated b-catenin may also directly regulate MYB. This was particularly relevant in light of another study proposing that MYB is a target of the Wnt pathway. 20 However, despite the presence of prospective TCF/LEF binding sites in the human and mouse MYB promoter (Supplementary Figure 2a-c) we were unable to show upregulation of the MYB promoter in the presence of an activated form of b-catenin lacking the first 89 amino acids. Strikingly, high concentrations of activated b-catenin plasmid inhibited MYB promoter activity (Figure 4a ). It is unclear whether this represents direct repression or the sequestration of transcription factors required for basal MYB promoter activity. In contrast, c-Myb induced its own promoter, consistent with previous findings. 21 Furthermore, endogenous c-Myb/MYB activity in HEK293 and NIH3T3 cells was unaffected by exogenous activated b-catenin (Figure 4b ; Supplementary Figure 2d) , although luciferase reporter assays with the archetypal b-catenin-responsive reporter pTOPFlash showed that the construct used for these assays had transactivation function. Taken together, these results show that the correlation between MYB and MYC expression in CRC is unlikely to be due to the common activation of both genes by deregulated Wnt signaling.
MYB and activated b-catenin cooperate to induce MYC reporter activation. Considering the mutual activation of b-catenin and MYB in CRC, in addition to MYC overexpression, we next considered whether MYB and activated b-catenin share MYC as a common gene target. This was assessed using chloramphenicol acetyltransferase (CAT) reporter assays with the human MYC promoter in HEK293 epithelial cells. HEK293 cells were used as they express very low levels of MYB while retaining a functional Wnt pathway. MYB conferred a dose-dependent increase in transcription from the MYC promoter, with a maximum level of 4.0-fold activation observed (Figure 5a ). It is also notable that increasing c-Myb beyond this maximum level leads to a progressive decline in reporter activation.
14 When similar levels of activated b-catenin were co-transfected with the MYC promoter, there was a more modest effect on reporter activity compared with c-Myb alone, with a twofold increase observed at best, in keeping with previous analyses (Figure 5b ). 11 The prominence of binding sites for both MYB and the b-catenin transcriptional partner TCF/LEF within the MYC promoter sequence indicates a possible convergence of these pathways in the activation of MYC. As expected from the previous dose-response curves, transfection of (approximately sixfold; determined by densitometry scans) in MYC mRNA expression than that achieved by the individual effectors alone. Changes in MYC mRNA levels associated with the expression of MYB and activated b-catenin were also reflected as an increase in c-Myc protein (Figure 6b ). It is apparent from these results that MYB and activated b-catenin also cooperate to support robust expression of endogenous MYC.
MYB and activated b-catenin bind to the endogenous MYC promoter. c-Myb and activated b-catenin may cooperate in regulating MYC by associating together at the cellular target gene promoter. To evaluate this, chromatin immunoprecipitation (ChIP) assays were carried out in HEK293 cells transfected with expression constructs for c-Myb and b-catenin. These experiments showed that both proteins were recruited to the MYC promoter (Figure 6c ). In the absence of transfected proteins, very little MYC promoter was detected in ChIP lysates, consistent with the minimal c-Myb/MYB expression and low amounts of endogenous nuclear b-catenin in this cell line.
To determine whether endogenous c-Myb and b-catenin bind to the genomic MYC promoter in human CRC cells, ChIP assays were performed in Colo201 cells. These cells express abundant levels of MYB 18 and MYC 22 and have an activated Wnt pathway through APC mutation. 6 As shown in Figure 6c , both c-Myb and b-catenin are enriched at the MYC promoter in these CRC cells. Numerous attempts were made to examine whether c-Myb and b-catenin, with or without TCF4, are able to form an endogenous complex in CRC cells or in HEK293 cells when overexpressed. However, no evidence for such complexes was obtained, although binding of b-catenin to TCF4 was readily established (data not shown). These observations indicate that that both transcription factors most likely engage the MYC promoter independently of each other. To further understand the mechanism by which cooperation between the two factors occurs, we assessed acetylation at the MYC promoter using an antibody directed toward a motif correlated with transcriptional activation, acetylated lysine 27 of histone H3. We found increased acetylated histone H3 (lysine 27) associated with the binding of both factors, but in particular c-Myb (data not shown). In a broader context, these data provide additional support for the proposition that the activation of MYC expression by deregulated Wnt signaling is more readily achieved in the presence of c-Myb.
Discussion
The Wnt pathway has an early and prominent function in CRC genesis through mutations in APC or b-catenin.
3,4,23 Analysis of APC Min/ þ mice and their corresponding predisposition to intestinal adenoma formation has allowed the cellular and molecular aspects of human familial adenomatous polyposis (FAP) to be understood. 24 The biology of adenoma formation needs to be considered in the context of how crypts are generated and maintained. In this regard, the Wnt pathway, [25] [26] [27] c-Myb, 2 and MYC 28,29 are particularly important. We observed that the normal kinetics of adenoma formation in APC Min/ þ mice is correspondingly and significantly delayed when c-myb is haploinsufficient. This is likely because of the need to drive strong expression of important gene targets such as MYC, as shown in the current study. It has been reported that intestine-specific knockout of c-myc reduces adenoma formation in APC Min/ þ mice. 30 We found a similar phenomenon in APC Min/ þ mice when one allele of c-myb is deleted. This is an especially important observation given that MYC is a common target for both MYB and the Wnt pathway in CRC. Certainly, deletion of either c-myb or c-myc has a critical effect on colonic crypt development, 2,31,32 whereas c-Myb is additionally necessary for appropriate maintenance of adult crypt homeostasis. 2 As a corollary, c-myb or c-myc expression is highly elevated in APC Min/ þ adenomas in the SI and colon indicating involvement of these in the inappropriate expansion of epithelial cells. The more slowly forming adenomas in APC Min/ þ Â c-myb þ /À mice showed a correspondingly reduced level of both c-myb and c-myc expression. Whether this finding reflects the availability of a single c-myb allele for activation in adenoma-prone APC Min/ þ intestinal epithelia is currently unclear. However, when these observations are considered together, it is clear that c-myb and c-myc are required for normal crypt biology, but when overexpressed are associated with carcinogenesis.
Given that MYC is normally targeted by both the MYB and Wnt pathways, these data suggest a prospective mechanism for cooperation in which activated Wnt signaling leads to upregulation of MYB, making it available for cooperative activation of target genes such as MYC. Previous work by others highlighted MYB as a potential Wnt target gene. 20 However, we did not observe activation of either the MYB promoter or endogenous gene by an activated form of b-catenin. This discrepancy between our results and those of van de Wetering et al. may derive from the normal cellular biology of c-Myb/MYB. Expression of dominant-negative TCF4 in CRC cells causes cellular differentiation, a process that occurs in concert with decreased MYB expression. Nevertheless, we cannot at this stage rule out MYB as a bona fide Wnt target gene in CRC. It is possible that the variation in findings stems from the different cell types used in each study.
c-Myb requires cooperating factors in a number of circumstances to exert its full transactivation potential. For instance, c-Myb is known to work in partnership with a number of proteins, including CBP, the C/EBPb family member NF-M, and p100, in regulating hemopoietic genes such as mim-1 (reviewed in Ramsay and Gonda 1 ). The present work extends this list of c-Myb partners to include b-catenin. We have confirmed previous reports that b-catenin alone activates the MYC promoter, but extended these observations by demonstrating that convergence with MYB leads to a more robust level of MYC promoter activity as well as expression from the endogenous gene locus. Our attempts to show direct interaction between the two factors were unsuccessful. The implication from this was that cooperative transactivation by the two factors is not achieved through physical association with each other, but rather through a mechanism that perhaps involves the independent binding of each factor to the target promoter, as shown in our ChIP assays. In further support of this assertion, ChIP assays against a histone motif correlated with transactivation showed increased acetylation at the MYC promoter associated with the presence of both factors, consistent with the increased levels of endogenous MYC mRNA and protein.
The potential that c-Myb/MYB and activated b-catenin cooperate in regulating other genes central to CRC has also been considered. One gene of particular interest was cyclooxygenase 2 (COX-2). The COX-2 promoter has both TCF4/LEF-1 33, 34 and MYB binding sites within it promoter region, whereas its counterpart COX-1 has none. 35 Expression of Cox-2 is increased markedly in APC Min/ þ intestinal adenomas (Supplementary Figure 3a) as reported by others. 36, 37 We observed cooperative induction of the human COX-2 promoter in the presence of submaximal levels of MYB with activated b-catenin, recapitulating the data described here for MYC (Supplementary Figure 3b-d) . This indicates that the cooperative interaction between MYB and activated b-catenin may extend beyond MYC alone to include the regulation of other genes important to adenoma formation and progression.
In conclusion, we have established a relationship between the two most commonly activated pathways in CRC in the generation of intestinal adenomas, a process that appears to function by cooperative regulation of CRC genes such as MYC. This cooperative mechanism of activation would be possible at the earliest stages of colonic crypt epithelial cell transformation where APC mutations are thought to initiate CRC, because MYB expression is a feature of normal colonocytes and thus available to work in cooperation with elevated levels of b-catenin. This work highlights the importance of discovering modes of therapeutic targeting of inappropriate MYB expression. 1 
Materials and Methods
Mice. C57Bl/6 APC min/ þ mice harboring an Apc allele mutation that encodes a truncated protein of 850 amino acids and c-myb þ /À knockout mice were interbred to generate compound heterozygous mice. They were observed for any signs intestinal bleeding or ill health according the Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee regulations. Sick mice were killed and examined for the presence of adenomas in the colon and SIs. Adenomas and histologically normal mucosa were collected and processed for total RNA using Trizol (Invitrogen).
cDNA microarray expression analysis. A gene expression database representing 229 tumor samples belonging to 13 histological types has been developed for the classification of different cancers. 38 Following intensity-based (LOWESS) and per gene median normalization of the array data, fold-change ratios for the genes MYB, MYC, and b-catenin (CTNNB1) were visualized across ordered cancer types using the programs Cluster and Treeview. All gene probes were confirmed by DNA sequencing.
Reporter assays. HEK293 or NIH3T3 cells were transfected with a combination of either 0.2 mg of CAT or 1 mg of luciferase reporter plasmid (pc-mycCAT, pTOPFlash, or pFOPFlash, 0.5-3 mg of effector plasmid (pACT-c-myb or pcDNA3.1-DN89-b-catenin) and 0.33 mg of transfection efficiency plasmid (pSV40-b-galactosidase) using Metafectene (Biontex) according to the manufacturer's instructions. The MYB promoter construct has been described in detail elsewhere. 39 Western blotting. Transfection of cells involved correspondingly higher amounts of plasmid effector DNAs per flask to recapitulate the ratios of effector DNAs to cell numbers used in the reporter studies. Proteins were partitioned into nuclear and cytoplasmic fractions by differential centrifugation in lysis buffer before separation on 10% polyacrylamide/SDS gels and transfer to PVDF membrane. Membranes were blocked in 10% non-fat skim milk powder and then probed with one of the following antibodies made up in 1% gelatin: mouse anti-c-Myb 1.1
(1 : 500), mouse anti-c-Myc tag, mouse anti-pan actin (1 : 2500; ICN Biomedical), and mouse anti-b-catenin. After washing, the membranes were probed with a goat anti-mouse secondary antibody conjugated to alkaline phosphatase (1 : 2500; Bio-Rad). Blots were developed using 5-bromo-4-chloro-3 0 -indolyphosphate p-toluidine salt and nitro-blue tetrazolium chloride reagents (Sigma).
MYB knockdown by RNA interference. The doxycycline-inducible lentiviral shRNA vector pLVTSH will be fully described elsewhere (Barry et al., in preparation). In brief, vectors encoding an MYB shRNA 5 0 -GAACCUCUUACA AUUUGCAGAAACACUUUCAUGAGAAGUGUUUCUGCAUUGUGUAAGAGGUU CUU-3 0 (with the bold sequences corresponding to sense and antisense MYB mRNA, respectively) and a scrambled control shRNA 5 0 -AUAAGAAU GUCCAUC AGUUACGCCAUAUUCAUGAGAUAUGGCGUAACUGAUGGACAUUCUUAUUU-3 0 were used. Lentivirus was generated by co-transfection of HEK293T cells with packaging plasmids using Lipofectamine 2000 (Invitrogen) as directed by the manufacturer. The supernatant was collected after 48 h, filtered through a 0.45 mm filter before being used to transduce Colo201 cells. These cells were FACS-sorted based on expression of pLVTSH-encoded eGFP. Cell were allowed to expand and then treated with 1 mg/ml doxycycline (Sigma) for 3 days. A sample of each culture was collected, washed in PBS and placed in Trizol, and subsequently processed for total RNA. MYB and MYC knockdown efficiency was assessed by Q-RT-PCR. A mouse anti-pan actin antibody and rabbit serum (Zymed) served as isotype controls. Antibody-protein-DNA complexes were collected using Protein A Sepharose beads and washed to remove nonspecifically bound protein-DNA adducts. The formaldehyde cross-links were reversed before the immunoprecipitates were assessed by PCR. ChIP samples were used undiluted and subjected to 27 cycles of PCR at 60 1C. Approximately 12% of the original sample was taken as the input control and subjected to the same PCR thermocycling. The following primers were used for amplification: for transfected HEK293 and Colo201cell studies-forward, 5 0 -GCCTGCGATGATTTATACTCACAG-3 0 ; reverse, 5 0 -CGGAGATTAGCGAGAGAGGATC-3 0 . These were designed using Primer Express software from Applied Biosystems. Chromatin immunoprecipitation assays. Q-RT-PCR was used to examine changes in acetylation levels at the endogenous MYC promoter associated with the binding of MYB and b-catenin. Approximately 1 Â 10 6 HEK293 cells were plated out in 100 mm dishes and transfected with 4 mg of either pcDNA3.1-DN89-b-catenin or pACT-c-Myb alone or in combination. The same number of cells were also plated and used as untransfected controls. ChIP assays were carried out 72 h after transfection. After fixation and sonication of the DNA, samples were precleared with Protein A Sepharose beads and treated with a rabbit acetylatedlysine27-specific antibody (Upstate Biotechnology). Rabbit serum (Zymed) served as an isotype control. Antibody-protein-DNA complexes were collected using Protein A Sepharose beads, washed, and the formaldehyde cross-links reversed before the immunoprecipitates were assessed by PCR. ChIP samples were diluted 15-fold in dH 2 O before use. Reaction mixtures and thermocycling were performed using SYBR Green according to the manufacturer's instructions in a PerkinElmer real-time PCR machine, model 7000 (Applied Biosystems). Primer sets were used to generate 100 bp amplicons and designed using Primer Express software from Applied Biosystems. Primer set 1: forward, 5 0 -CTGGAAGGCAGCCAAATTTTA-3 0 ; reverse, 5 0 -AAAATGCATCGATTCTGATCAAAG-3 0 . Primer set 2: forward, 5 0 -AGG ACAAGGATGCGGTTTGT-3 0 ; reverse, 5 0 -CTACGCGCGCCTACCATTT-3 0 . Forty cycles of PCR were used at a temperature of 60 1C. Analysis of the primary data was undertaken as described. 40 
RT-PCR analysis of endogenous
